The United States has 36,000 Jynneos monkeypox vaccine doses
According to the Health and Human Services Department, the United States has more than 36,000 doses of the Jynneos monkeypox vaccine in its strategic national stockpile.
The Centers for Disease Control and Prevention is sending the vaccine to people who have had high-risk exposures to the virus in an effort to stop it from spreading. The U.S. has identified 25 confirmed or presumed cases of monkeypox cases across 12 states as of Friday.
The U.S. government has asked Danish biotech company Bavarian Nordic to send over 36,000 more doses of the vaccine Jynneos in the near future. The company is holding more than 1 million doses of the vaccine, which the federal government can request more of if needed.
The monkeypox pandemic is the world’s largest outside of Africa. So far, it has infected nearly 800 people in 27 countries. The World Health Organization has received reports of over 770 confirmed monkeypox cases in 27 nations. Most of the cases are in Europe, particularly Portugal, Spain, and the United Kingdom.
Jynneos was licensed by the Food and Drug Administration in 2019 to help protect people at high risk of smallpox or monkeypox. The only vaccine that can protect against monkeypox is the two-dose vaccination. The United States also has more than 100 million doses of the older generation smallpox vaccine, ACAM2000. ACAM2000 is made by Emergent BioSolutions.
1,200 doses of Jynneos and ACAM2000 have been given to people in the United States who are at high risk for monkeypox infection, according to Dr. Raj Panjabi.
The ACAM2000 vaccine is authorized by the FDA to protect people from smallpox. It can also be used to help protect people from monkeypox. Monkeypox is a virus that is in the same family as smallpox, but it is much less severe.
The US is sending an oral antiviral called tecovirimat to people who have been infected with monkeypox. This antiviral was first approved by the FDA in 2018 for smallpox treatment, but it may also be used against monkeypox. The CDC has a program that allows this antiviral to be used for people with monkey
The CDC usually advocates Jynneos over ACAM2000, which has unpleasant consequences. The live mild virus strain in the same family as monkeypox and smallpox that is used in ACAM2000 may still spread throughout the human body and to other individuals.
A cold sore may spread to other areas of the patient’s body if they scratch their blister and then rub their eye, resulting in vision damage. The virus can also spread from one family member to another, which might be harmful if a loved one has a weak immune system or is pregnant or breastfeeding. The FDA has advised that individuals who receive ACAM2000 must take special precautions to avoid spreading the virus via their injection site.
The virus in the vaccine can spread to the fetus in pregnant women and cause stillbirth. People with weak immune systems face a risk that the virus will uncontrollably spread and cause a dangerous infection. Individuals who have skin conditions like eczema or atopic dermatitis are likewise susceptible to the virus spreading on their skin and developing a life-threatening infection. ACAM2000 is also linked with an increased risk of heart inflammation, known as myocarditis and pericarditis.
The vaccine uses a mild virus that cannot spread to people. This means that it has fewer negative effects.
According to Mark Slifka, an immunologist at Oregon Health & Science University, the new vaccine has shown excellent levels of protection against monkeypox in animal tests and is anticipated to provide 85% protection against the virus, similar to previous versions of smallpox vaccines. a new vaccine and less is known about how well it works in humans. However, the vaccine did well in studies with people and should protect them from deadly illnesses.
The worldwide monkeypox outbreak has concerned public health experts because the viral infection is unusual to spread so rapidly outside of West and Central Africa. The virus has historically traveled from rats to humans in isolated villages in Africa, but this time it is spreading faster.
According to Slifka, the virus is now spreading better among humans through close physical contact than it did previously.